Inversago

News

Sales of its obesity therapies may be accelerating, but Novo Nordisk is showing no signs of pushing the brake pedal on investments in the category.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.